Elan Pharmaceuticals (NYSE: ELN), a Boston-based subsidiary of the Irish pharmaceutical manufacturer Elan Corporation, pleaded guilty Monday to charges related to the improper marketing of the epilepsy drug Zonegran.
The company agreed to pay a total of $203.5 million to resolve all federal and state Medicaid claims related to the marketing of the drug.
Elan was accused of a misdemeanor violation of the Food Drug and Cosmetic Act in the case.
via bizjournals.com
No comments:
Post a Comment